Ads
related to: clinically significant macular edema treatment options- DME FAQs
Get Answers To Frequently
Asked Questions About DME
- Download The Amsler Grid
Use This Test To Help Monitor
Your Vision Between Appointments
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Appointment Tips
Get Tips And Useful Information
To Talk To Your Specialist
- Resource Library
Useful Digital Resources & Tools
To Support Your Treatment Journey
- DME FAQs
Search results
Results From The WOW.Com Content Network
The causes of macular edema are numerous and different causes may be inter-related. It is commonly associated with diabetes.Chronic or uncontrolled diabetes type 2 can affect peripheral blood vessels including those of the retina which may leak fluid, blood and occasionally fats into the retina causing it to swell.
The American Academy of Ophthalmology practice guidelines recommend laser coagulation for people who have both mild to moderate nonproliferative diabetic retinopathy (NPDR) and clinically significant macular edema outside the fovea; treatment with anti-VEGF drugs is better than laser coagulation for clinically significant macular edema in the fovea. [1]
Findings include delayed venous filling, hypofluorescence caused by hemorrhage and capillary nonperfusion, dilation and tortuosity of veins, leakage due to neovascularization and macular edema. Optical coherence tomography is an adjunctive test in branch retinal vein occlusion. Macular edema is commonly seen on optical coherence tomography exams.
Comparison of Age-Related Macular Degeneration Treatments Trial: Lucentis-Avastin Trial: This two-year, multicenter clinical trial compared the effectiveness of two treatments used for AMD: Lucentis and Avastin. It showed that both treatments are equally effective in treating AMD and improving vision, whether used monthly or as needed.
Diabetic retinopathy (also known as diabetic eye disease) is a medical condition in which damage occurs to the retina due to diabetes.It is a leading cause of blindness in developed countries and one of the lead causes of sight loss in the world, even though there are many new therapies and improved treatments for helping people live with diabetes.
The number of injections tripled to 15,000 in 2002 when triamcinolone injections were first used to treat diabetic macular oedema. [2] [3] This use continued to drive an increase to 83,000 injections in 2004. [2] In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000. [2]
Ads
related to: clinically significant macular edema treatment options